Compare Incyte Corporation (INCY) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Iron Mountain Inc — how do they compare? Incyte Corporation trades at $113.24 (market cap $22.85B), while Iron Mountain Inc trades at $114.1 (market cap $34.46B). The key difference: Iron Mountain Inc is the larger of the two by market cap, and Iron Mountain Inc pays a 2.99% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Iron Mountain Inc for 80 Days on average.
| INCY | IRM | |
|---|---|---|
Market Cap | $22.85B | $34.46B |
Volume | 1,927,029 | 1,379,608 |
Sector | Health | Real Estate |
52-Week High | $129.93 | $133.06 |
52-Week Low | $83.80 | $78.86 |
Typical Hold Time | 33 Days | 80 Days |
Enterprise Value | $18.35B | $53.87B |
Dividend Yield | — | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Iron Mountain (IRM) trades at $114.51, down 1.05% on the day, with a bearish technical signal and elevated valuation metrics like a P/E of 82.09. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.60 surpassing the $0.543 forecast. The company is expanding its data center pipeline and digital solutions, targeting 300MW capacity, while revenue grew to $6.90 billion in 2025. However, net income margin has declined to 2.09%, and debt-to-asset ratio rose to 79.04% in 2025, indicating financial leverage concerns.
The outlook is mixed: strong analyst consensus with a $142.75 price target and 66.7% buy ratings support upside potential, but high debt, margin pressure, and bearish technicals pose risks. Growth in data centers and digital services offers opportunity, yet investors must weigh leverage and profitability trends against expansion prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
